- ¥6bn
- ¥1bn
- ¥8m
Annual balance sheet for Noile-Immune Biotech, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
| Standards: | JAS | JAS | — | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2,548 | 4,141 | 4,521 | 5,556 | 4,671 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 52 | 53 | — | 67 | 62.4 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,659 | 4,225 | 4,584 | 5,717 | 4,775 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0 | 0 | 0 | — | — |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,674 | 4,271 | 4,641 | 5,779 | 4,800 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 70.6 | 80.5 | 335 | 86.3 | 69.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 75.9 | 85.7 | 340 | 91.5 | 74.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 2,598 | 4,185 | 4,301 | 5,687 | 4,725 |
| Total Liabilities & Shareholders' Equity | 2,674 | 4,271 | 4,641 | 5,779 | 4,800 |
| Total Common Shares Outstanding |